ClinicalTrials.gg
RecruitingNCT06959095ENDURA-1Updated Oct 5, 2026

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

A Phase 3 interventional study of Depemokimab and Placebo in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Recruiting at 281 sites in 23 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.
Updated Oct 5, 2026First sites in 20 new countriesPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
981
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.

Planned enrollment
21st of 236
981 · median 101
Started
2025
with 3 others
Phase 3
65 of 276
5 open now
Registered
269th of 276
by date

Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 21st largest by planned enrollment of the 236 interventional ones that give a count, is one of 4 that started in 2025, is one of 65 in phase 3, and was the 269th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, or all of them as a file.
02

Study summary

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • Depemokimab
  • GSK3511294
  • Eosinophilic phenotype
  • Chronic obstructive pulmonary disease
  • (COPD)
  • Moderate COPD
  • Severe COPD
  • Uncontrolled Moderate to Severe Chronic Obstructive Pulmonary Disease
  • Exacerbations
  • Placebo
  • Type 2 inflammation
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be greater than or equal to (>=) 40 to less than or equal to (\<=) 80 years of age, at the time of signing the
  • Elevated blood eosinophil count (BEC).
  • Moderate to severe with frequent exacerbations, defined as:

    • A clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year
    • A post-bronchodilator (FEV1)/forced vital capacity (FVC) ratio of less than (\<) 0.70 and a post- bronchodilator FEV1 >30 percent (%) and \<= 80% predicted normal values
    • A well-documented history of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening
  • COPD assessment test (CAT) score >=10 at Visit 1
  • Smoking status: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years.
  • Participants should be on optimized inhaler therapy, defined as inhaled (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1
  • (BMI) >=16 kilogram per square meter (kg/m\^2).
  • Male or eligible female participants

Exclusion criteria

Exclusion Criteria:

The following subjects are excluded:

  • Participants with a current or prior physician diagnosis of asthma
  • Other lung disease: The Investigator must judge that is the primary diagnosis accounting for the clinical manifestations of the lung disease
  • Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1
  • Lung resection: Participants with a history of, or plan for lung volume reduction surgery / endobronchial valve procedure
  • Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1.
  • Continuous oxygen: Participants requiring oxygen supplementation for more than 16 hours per day to maintain resting oxygen saturation greater than 88%
  • Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension
  • Chronic hypercapnia requiring Non-invasive positive pressure ventilation (NIPPV) use (including Bi-Level Positive Airway Pressure [BiPAP] or Continuous Positive Airway Pressure [CPAP])
  • Unstable cardiovascular disease or arrhythmia.
  • Parasitic Infection: Participants with a known, pre-existing parasitic infection within 6 months of Screening (Visit 1)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
981 participants (estimated)

Study arms

  • Experimental
    Depemokimab

    Participants will be administered depemokimab along with standard of care (SoC).

    Biological: Depemokimab

  • Placebo comparator
    Placebo

    Participants will be administered placebo along with SoC.

    Drug: Placebo

Interventions

  • BiologicalDepemokimab

    Depemokimab as a sterile liquid formulation will be administered.

    Also known as: GSK3511294

  • DrugPlacebo

    Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered.

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Moderate/Severe Exacerbations

    Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (i.e., greater than or equal to \[\>=\] 24 hours) or result in death. The frequency of moderate/ severe exacerbations expressed as an annualized exacerbation rate will be evaluated.

    Time frame: From Baseline up to Week 104

Secondary outcomes

  1. Time to First Moderate/Severe Exacerbation

    Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (i.e., greater than or equal to \[\>=\] 24 hours) or result in death.

    Time frame: From Baseline up to Week 104

  2. Change From Baseline in St. Georges Respiratory Questionnaire (SGRQ) Total Score at Week 52

    The SGRQ total score will be measured using the SGRQ for COPD \[SGRQ-C\]. The SGRQ-C is a 40-item participant questionnaire designed to measure health impairment by addressing the frequency of respiratory symptoms (questions 1-7) and the participant's current state (questions 8-14). The questions are designed to be self-completed by the participant. The total score will be calculated on 0-100 rating scale and scores expressed as a percentage of overall impairment. Higher scores indicate greater impairment of health.

    Time frame: From Baseline up to Week 52

  3. Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total Score at Week 52

    E-RS: COPD consists of 11 items from the 14-item Exacerbations of Chronic Pulmonary Disease Tool - Patient Reported Outcomes (EXACT) instrument. E-RS: COPD is intended to capture information related to the respiratory symptoms of COPD, i.e., breathlessness, cough, sputum production, chest congestion, and chest tightness. The ERS: COPD has a scoring range of 0 to 40, higher scores indicate more severe symptoms.

    Time frame: From Baseline up to Week 52

  4. Annualized Rate of Exacerbations Requiring Emergency Department (ED) Visit or Hospitalization

    Annualized rate of exacerbations requiring ED Visit or Hospitalization (For pooled analysis across studies 222714 and 222725) will be assessed.

    Time frame: From Baseline up to Week 104

  5. Annualized Rate of Severe Exacerbations

    Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (i.e., greater than or equal to \[\>=\] 24 hours) or result in death. Annualized rate of severe exacerbations (For pooled analysis across studies 222714 and 222725) will be assessed.

    Time frame: From Baseline up to Week 104

07

Study locations

281 of 281 sites recruiting
  • GSK Investigational Site
    Bakersfield, California 93301, United States
    Recruiting
  • GSK Investigational Site
    Modesto, California 95355-4046, United States
    Recruiting
  • GSK Investigational Site
    Newport Beach, California 92663, United States
    Recruiting
  • GSK Investigational Site
    Wilmington, Delaware 19803, United States
    Recruiting
  • GSK Investigational Site
    Bradenton, Florida 34209, United States
    Recruiting
  • GSK Investigational Site
    Brandon, Florida 33511-5706, United States
    Recruiting
  • GSK Investigational Site
    Hialeah, Florida 33012, United States
    Recruiting
  • GSK Investigational Site
    Hialeah, Florida 33016, United States
    Recruiting
  • GSK Investigational Site
    Loxahatchee Groves, Florida 33470, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33126, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33155, United States
    Recruiting
  • GSK Investigational Site
    Miami Lakes, Florida 33016, United States
    Recruiting
  • GSK Investigational Site
    Orange City, Florida 32763, United States
    Recruiting
  • GSK Investigational Site
    Palm Springs, Florida 33406, United States
    Recruiting
  • GSK Investigational Site
    Palmetto Bay, Florida 33176-7296, United States
    Recruiting
  • GSK Investigational Site
    Pensacola, Florida 32503-2698, United States
    Recruiting
  • GSK Investigational Site
    Tamarac, Florida 33321, United States
    Recruiting
  • GSK Investigational Site
    Tampa, Florida 33614, United States
    Recruiting
  • GSK Investigational Site
    The Villages, Florida 32162, United States
    Recruiting
  • GSK Investigational Site
    Riverdale, Georgia 30274, United States
    Recruiting
  • GSK Investigational Site
    Stonecrest, Georgia 30038, United States
    Recruiting
  • GSK Investigational Site
    Chicago, Illinois 60611, United States
    Recruiting
  • GSK Investigational Site
    Baltimore, Maryland 21224, United States
    Recruiting
  • GSK Investigational Site
    Clarkston, Michigan 48346, United States
    Recruiting
  • GSK Investigational Site
    Flint, Michigan 48504-4730, United States
    Recruiting
  • GSK Investigational Site
    St Louis, Missouri 63110, United States
    Recruiting
  • GSK Investigational Site
    Henderson, Nevada 89052-5015, United States
    Recruiting
  • GSK Investigational Site
    Las Vegas, Nevada 89123-2874, United States
    Recruiting
  • GSK Investigational Site
    Reno, Nevada 89502, United States
    Recruiting
  • GSK Investigational Site
    North Massapequa, New York 11758, United States
    Recruiting
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • GSK Investigational Site
    Winston-Salem, North Carolina 27104, United States
    Recruiting
  • GSK Investigational Site
    Greenville, South Carolina 29607, United States
    Recruiting
  • GSK Investigational Site
    Rock Hill, South Carolina 29732, United States
    Recruiting
  • GSK Investigational Site
    Franklin, Tennessee 37067, United States
    Recruiting
  • GSK Investigational Site
    Corsicana, Texas 75110, United States
    Recruiting
  • GSK Investigational Site
    Dallas, Texas 75234, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77058-2805, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77084, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77089, United States
    Recruiting
  • GSK Investigational Site
    McKinney, Texas 75069, United States
    Recruiting
  • GSK Investigational Site
    Pearland, Texas 77584, United States
    Recruiting
  • GSK Investigational Site
    La Plata, Provincia de Bs AS 1900, Argentina
    Recruiting
  • GSK Investigational Site
    Buenos Aires, 1023, Argentina
    Recruiting
  • GSK Investigational Site
    Buenos Aires, 7600, Argentina
    Recruiting
  • GSK Investigational Site
    Buenos Aires, C1121ABE, Argentina
    Recruiting
  • GSK Investigational Site
    Buenos Aires, C1425AGC, Argentina
    Recruiting
  • GSK Investigational Site
    Buenos Aires, C1425BEN, Argentina
    Recruiting
  • GSK Investigational Site
    Ciudad Autonoma de Bueno, C1414AIF, Argentina
    Recruiting
  • GSK Investigational Site
    Mendoza, 5500, Argentina
    Recruiting
  • GSK Investigational Site
    Mendoza, M5500CCG, Argentina
    Recruiting
  • GSK Investigational Site
    Paraná, 3100, Argentina
    Recruiting
  • GSK Investigational Site
    Rosario, S2002OJN, Argentina
    Recruiting
  • GSK Investigational Site
    San Juan Bautista, 1888, Argentina
    Recruiting
  • GSK Investigational Site
    San Miguel de Tucumán, 4000, Argentina
    Recruiting
  • GSK Investigational Site
    San Miguel de Tucumán, T4000IFL, Argentina
    Recruiting
  • GSK Investigational Site
    San Miguel de Tucumán, T4000, Argentina
    Recruiting
  • GSK Investigational Site
    Aalst, 9300, Belgium
    Recruiting
  • GSK Investigational Site
    Genk, 3600, Belgium
    Recruiting
  • GSK Investigational Site
    Kortrijk, 8500, Belgium
    Recruiting
  • GSK Investigational Site
    Liège, 4000, Belgium
    Recruiting
  • GSK Investigational Site
    Liège, 4000, Belgium
    Recruiting
  • GSK Investigational Site
    Namur, 5101, Belgium
    Recruiting
  • GSK Investigational Site
    Sint-Niklaas, 9100, Belgium
    Recruiting
  • GSK Investigational Site
    Richmond, British Columbia V6V 2L1, Canada
    Recruiting
  • GSK Investigational Site
    Ajax, Ontario L1S 2J5, Canada
    Recruiting
  • GSK Investigational Site
    Toronto, Ontario M5T 3A9, Canada
    Recruiting
  • GSK Investigational Site
    Windsor, Ontario N8X 1T3, Canada
    Recruiting
  • GSK Investigational Site
    Saint-Charles-Borromée, Quebec J6E 2B4, Canada
    Recruiting
  • GSK Investigational Site
    Sherbrooke, Quebec J1L 0H8, Canada
    Recruiting
  • GSK Investigational Site
    Saskatoon, Saskatchewan S7N 0W8, Canada
    Recruiting
  • GSK Investigational Site
    Curicó, 3341643, Chile
    Recruiting
  • GSK Investigational Site
    Haikou, Hainan 570311, China
    Recruiting
  • GSK Investigational Site
    Changsha, Hunan 410015, China
    Recruiting
  • GSK Investigational Site
    Chengdu, Sichuan 611130, China
    Recruiting
  • GSK Investigational Site
    Beijing, 100020, China
    Recruiting
  • GSK Investigational Site
    Beijing, 100034, China
    Recruiting
  • GSK Investigational Site
    Changchun, 130021, China
    Recruiting
  • GSK Investigational Site
    Changchun, 130041, China
    Recruiting
  • GSK Investigational Site
    Changsha, 410013, China
    Recruiting
  • GSK Investigational Site
    Chengdu, 610041, China
    Recruiting
  • GSK Investigational Site
    Chongqing, 400038., China
    Recruiting
  • GSK Investigational Site
    Dongguan, 523059, China
    Recruiting
  • GSK Investigational Site
    Fuyang, 236000, China
    Recruiting
  • GSK Investigational Site
    Guangzhou, 510150, China
    Recruiting
  • GSK Investigational Site
    Guangzhou, 510180, China
    Recruiting
  • GSK Investigational Site
    Guilin, 541002, China
    Recruiting
  • GSK Investigational Site
    Hangzhou, 310000, China
    Recruiting
  • GSK Investigational Site
    Hangzhou, 310005, China
    Recruiting
  • GSK Investigational Site
    Hefei, 230001, China
    Recruiting
  • GSK Investigational Site
    Hohhot, 010017, China
    Recruiting
  • GSK Investigational Site
    Hohhot, 010050, China
    Recruiting
  • GSK Investigational Site
    Huizhou, 516000, China
    Recruiting
  • GSK Investigational Site
    Huizhou, 516001, China
    Recruiting
  • GSK Investigational Site
    Jiangmen, 529000, China
    Recruiting
  • GSK Investigational Site
    Jiangmen, 529030, China
    Recruiting
  • GSK Investigational Site
    Jiangsu, 221004, China
    Recruiting
  • GSK Investigational Site
    Jiangxi, China
    Recruiting
  • GSK Investigational Site
    Jinan, 250012, China
    Recruiting
  • GSK Investigational Site
    Kunming, 650032, China
    Recruiting

Showing the first 100 of 281 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2028, 41 months after the start.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 41 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Aug 2029 → Dec 2028 and completion Aug 2029 → Feb 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 6, 2025
StartActual
Jun 20, 2025
Primary completionEst.
Dec 13, 2028was Aug 2029
CompletionEst.
Feb 14, 2029was Aug 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
266 sites added — first sites in Argentina, Belgium, Canada, Chile, Croatia and 15 more
All 20 countries

Argentina, Belgium, Canada, Chile, Croatia, Denmark, France, Germany, Hungary, Ireland, Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye)

Show 266 added (47 China, 46 Japan, 38 United States, 17 Germany, 16 Spain, 15 Argentina, 11 France, 9 Poland, 9 Portugal, 8 Netherlands, 7 Belgium, 7 Canada, 7 Taiwan, 6 Ireland, 5 Turkey (Türkiye), 4 Hungary, 3 Denmark, 3 Sweden, 2 Croatia, 2 Slovakia, 2 Switzerland, 1 Chile, 1 Norway)
  • GSK Investigational Site · Bakersfield, United States
  • GSK Investigational Site · Modesto, United States
  • GSK Investigational Site · Newport Beach, United States
  • GSK Investigational Site · Wilmington, United States
  • GSK Investigational Site · Bradenton, United States
  • GSK Investigational Site · Brandon, United States
  • GSK Investigational Site · Hialeah, United States
  • GSK Investigational Site · Hialeah, United States
  • GSK Investigational Site · Miami, United States
  • GSK Investigational Site · Miami Lakes, United States
  • GSK Investigational Site · Orange City, United States
  • GSK Investigational Site · Palm Springs, United States
  • GSK Investigational Site · Palmetto Bay, United States
  • GSK Investigational Site · Pensacola, United States
  • GSK Investigational Site · Tamarac, United States
  • GSK Investigational Site · Tampa, United States
  • GSK Investigational Site · The Villages, United States
  • GSK Investigational Site · Riverdale, United States
  • GSK Investigational Site · Stonecrest, United States
  • GSK Investigational Site · Chicago, United States
  • GSK Investigational Site · Baltimore, United States
  • GSK Investigational Site · Clarkston, United States
  • GSK Investigational Site · Flint, United States
  • GSK Investigational Site · St Louis, United States
  • GSK Investigational Site · Henderson, United States
  • GSK Investigational Site · Las Vegas, United States
  • GSK Investigational Site · Reno, United States
  • GSK Investigational Site · North Massapequa, United States
  • GSK Investigational Site · Winston-Salem, United States
  • GSK Investigational Site · Winston-Salem, United States
  • …and 236 more on the registry record
Oct 5, 2026
Primary completion
Aug 20, 2029→Dec 13, 2028
Oct 5, 2026
Study completion
Aug 20, 2029→Feb 14, 2029
Oct 5, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedContinuous oxygen: Participants requiring oxygen supplementation for more than 1216 hours per day. to maintain resting oxygen saturation greater than 88%
Oct 5, 2026
Interventions
Added Biological: Depemokimab; removed Drug: Depemokimab
Oct 5, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedChange From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total Score at Week 52Time frame: From Baseline up to Week 52
Oct 5, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • GSK Investigational Site · Miami, United StatesContact person changed (no phone or email listed)
  • GSK Investigational Site · Corsicana, United StatesContact person changed (no phone or email listed)
  • GSK Investigational Site · Qingyuan, ChinaContact person changed (no phone or email listed)
  • GSK Investigational Site · Tokyo, JapanContact person changed (no phone or email listed)
Oct 5, 2026
Title
Depemokimab as an Extended treatmeNtTreatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    266 sites added — first sites in Argentina, Belgium, Canada, Chile, Croatia and 15 more
    All 20 countries

    Argentina, Belgium, Canada, Chile, Croatia, Denmark, France, Germany, Hungary, Ireland, Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye)

    Show 266 added (47 China, 46 Japan, 38 United States, 17 Germany, 16 Spain, 15 Argentina, 11 France, 9 Poland, 9 Portugal, 8 Netherlands, 7 Belgium, 7 Canada, 7 Taiwan, 6 Ireland, 5 Turkey (Türkiye), 4 Hungary, 3 Denmark, 3 Sweden, 2 Croatia, 2 Slovakia, 2 Switzerland, 1 Chile, 1 Norway)
    • GSK Investigational Site · Bakersfield, United States
    • GSK Investigational Site · Modesto, United States
    • GSK Investigational Site · Newport Beach, United States
    • GSK Investigational Site · Wilmington, United States
    • GSK Investigational Site · Bradenton, United States
    • GSK Investigational Site · Brandon, United States
    • GSK Investigational Site · Hialeah, United States
    • GSK Investigational Site · Hialeah, United States
    • GSK Investigational Site · Miami, United States
    • GSK Investigational Site · Miami Lakes, United States
    • GSK Investigational Site · Orange City, United States
    • GSK Investigational Site · Palm Springs, United States
    • GSK Investigational Site · Palmetto Bay, United States
    • GSK Investigational Site · Pensacola, United States
    • GSK Investigational Site · Tamarac, United States
    • GSK Investigational Site · Tampa, United States
    • GSK Investigational Site · The Villages, United States
    • GSK Investigational Site · Riverdale, United States
    • GSK Investigational Site · Stonecrest, United States
    • GSK Investigational Site · Chicago, United States
    • GSK Investigational Site · Baltimore, United States
    • GSK Investigational Site · Clarkston, United States
    • GSK Investigational Site · Flint, United States
    • GSK Investigational Site · St Louis, United States
    • GSK Investigational Site · Henderson, United States
    • GSK Investigational Site · Las Vegas, United States
    • GSK Investigational Site · Reno, United States
    • GSK Investigational Site · North Massapequa, United States
    • GSK Investigational Site · Winston-Salem, United States
    • GSK Investigational Site · Winston-Salem, United States
    • …and 236 more on the registry record
    Primary completion Aug 20, 2029→Dec 13, 2028
    Study completion Aug 20, 2029→Feb 14, 2029
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedContinuous oxygen: Participants requiring oxygen supplementation for more than 1216 hours per day. to maintain resting oxygen saturation greater than 88%
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChange From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total Score at Week 52Time frame: From Baseline up to Week 52
    Interventions Added Biological: Depemokimab; removed Drug: Depemokimab
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • GSK Investigational Site · Miami, United StatesContact person changed (no phone or email listed)
    • GSK Investigational Site · Corsicana, United StatesContact person changed (no phone or email listed)
    • GSK Investigational Site · Qingyuan, ChinaContact person changed (no phone or email listed)
    • GSK Investigational Site · Tokyo, JapanContact person changed (no phone or email listed)
    Title Depemokimab as an Extended treatmeNtTreatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
    + 3 other changes: verification date, design details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06959095
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 6, 2025
Start date
Jun 20, 2025
Primary completion
Dec 13, 2028 (estimated)
Completion
Feb 14, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Depemokimab

Start the discussion